AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9648044 — intervention group
Group type: EXPERIMENTAL
Intervention: School policies regarding medication carrying
Number of subjects: 161
Study 7990468 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate to severe problem drinking
Number of subjects: 369
Study 7990468 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild problem drinking
Number of subjects: 369
Study 7990468 — intervention group
Group type: EXPERIMENTAL
Intervention: Problem drinking defined by CAGE Questionnaire and other indicators
Number of subjects: 369
Study 7990468 — intervention group
Group type: EXPERIMENTAL
Intervention: Social anxiety
Number of subjects: 369
Study 7990468 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental drinking
Number of subjects: 369
Study 2537561 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril 20 mg once daily
Number of subjects: 142
Study 2537561 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril 10 mg twice daily
Number of subjects: 142
Study 2537561 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (overall group)
Number of subjects: 142
Study 31928949 — intervention group
Group type: EXPERIMENTAL
Intervention: Subanesthetic ketamine (0.5 mg/kg)
Number of subjects: 29
Study 31928949 — intervention group
Group type: COMPARATOR
Intervention: Placebo saline infusion
Number of subjects: 29
Study 29450737 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily oral hygiene intervals (12 and 24 hours)
Number of subjects: 52
Study 29450737 — intervention group
Group type: COMPARATOR
Intervention: Extended oral hygiene intervals (48 and 72 hours)
Number of subjects: 52
Study 28194525 — intervention group
Group type: EXPERIMENTAL
Intervention: SoluMatrix diclofenac 35 mg TID
Number of subjects: 305
Study 28194525 — intervention group
Group type: EXPERIMENTAL
Intervention: SoluMatrix diclofenac 35 mg BID
Number of subjects: 305
Study 28194525 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 305
Study 28194525 — intervention group
Group type: EXPERIMENTAL
Intervention: SoluMatrix diclofenac 35 mg TID and BID
Number of subjects: 305
Study 26496111 — intervention group
Group type: EXPERIMENTAL
Intervention: Transfusion of red blood cells (RBC) of varying storage ages
Number of subjects: 125
Study 23291926 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal cone therapy
Number of subjects: 22
Study 23291926 — intervention group
Group type: COMPARATOR
Intervention: Control group (HRT only)
Number of subjects: 22
Study 21073974 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous HCT
Number of subjects: 30
Study 21073974 — intervention group
Group type: COMPARATOR
Intervention: Allogeneic HCT
Number of subjects: 30
Study 19339099 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A (no anchors)
Number of subjects: 45
Study 19339099 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B (with mini fibre-reinforced composite anchors)
Number of subjects: 45
Study 19339099 — intervention group
Group type: COMPARATOR
Intervention: Group C (resin composite buildups)
Number of subjects: 45
Study 17295632 — intervention group
Group type: EXPERIMENTAL
Intervention: Active rTMS
Number of subjects: 43
Study 17295632 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study 15522553 — intervention group
Group type: EXPERIMENTAL
Intervention: 5‐fluoro‐uracyl‐epirubicin‐cyclophosphamide (FEC) - six cycles
Number of subjects: 40
Study 15522553 — intervention group
Group type: COMPARATOR
Intervention: docetaxel‐based chemotherapy - six cycles (DXL-epirubicin: 13 patients, DXL alone: 15 patients)
Number of subjects: 40
Study 11553189 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin 500 mg b.i.d. for 6 months
Number of subjects: 40
Study 11553189 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 6 months
Number of subjects: 40
Study 8831216 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 ml Iopamidol (300 mgI/ml), at a rate of 2 ml/sec
Number of subjects: 20
Study 8831216 — intervention group
Group type: EXPERIMENTAL
Intervention: 120 ml, 3 ml/sec
Number of subjects: 20
Study 8831216 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 ml, 3 ml/sec
Number of subjects: 20
Study 8831216 — intervention group
Group type: EXPERIMENTAL
Intervention: biphasic method, initial 100 ml, 3.3 ml/sec; remaining 50 ml, 1.6 ml/sec
Number of subjects: 20
Study 8831216 — intervention group
Group type: EXPERIMENTAL
Intervention: three-phase dynamic helical CT using protocol (4)
Number of subjects: 20
Study 8831216 — intervention group
Group type: EXPERIMENTAL
Intervention: three-phase dynamic helical CT
Number of subjects: 20
Study 2248385 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural morphine and clonidine (group 1; n = 45)
Number of subjects: 91
Study 2248385 — intervention group
Group type: COMPARATOR
Intervention: Epidural morphine alone (group 2; n = 46)
Number of subjects: 91
Study 7437248 — intervention group
Group type: EXPERIMENTAL
Intervention: Colchicine (1.0 mg daily for 8 days)
Number of subjects: 8
Study 7437248 — intervention group
Group type: COMPARATOR
Intervention: Placebo (daily for 8 days)
Number of subjects: 8
Study 30461542 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Number of subjects: 0
Study 30461542 — intervention group
Group type: COMPARATOR
Intervention: Tocilizumab and Abatacept
Number of subjects: 0
Study 30461542 — intervention group
Group type: EXPERIMENTAL
Intervention: Abatacept and Ustekinumab
Number of subjects: 0
Study 30461542 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab and Tumor Necrosis Factor Inhibitors (including Certolizumab)
Number of subjects: 0
Study 26708726 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradialytic parenteral nutrition (IDPN) plus standardized nutritional counseling
Number of subjects: 107
Study 26708726 — intervention group
Group type: COMPARATOR
Intervention: Standardized nutritional counseling only (Control)
Number of subjects: 107
Study 25982143 — intervention group
Group type: EXPERIMENTAL
Intervention: Low saturated fat-oriented dietary intervention
Number of subjects: 521
Study 25982143 — intervention group
Group type: COMPARATOR
Intervention: Control group (no dietary intervention)
Number of subjects: 521
Study 25982143 — intervention group
Group type: EXPERIMENTAL
Intervention: Adiponectin ≤ median
Number of subjects: 521
Study 25982143 — intervention group
Group type: EXPERIMENTAL
Intervention: Adiponectin
Number of subjects: 521
Study 25467396 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental practice (MP) and mirror therapy (MT) associated with conventional physical therapy training (CPTT)
Number of subjects: 7
Study 22788263 — intervention group
Group type: EXPERIMENTAL
Intervention: Guanfacine extended release (GXR) added to stimulant monotherapy
Number of subjects: 461
Study 22788263 — intervention group
Group type: COMPARATOR
Intervention: Stimulant monotherapy
Number of subjects: 461
Study 21068701 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus (Tac)
Number of subjects: 253
Study 21068701 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporine (CsA)
Number of subjects: 253
Study 17880485 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer education programme consisting of four one-hour sessions targeting evidence-based knowledge, myths and misconceptions, normative, attitudinal and control influences over evidence-based fever management.
Number of subjects: 0
Study 17880485 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail).
Number of subjects: 0
Study 15479705 — intervention group
Group type: EXPERIMENTAL
Intervention: PACE intervention (two visits with GP and two telephone booster calls by a physical activity counselor)
Number of subjects: 29
Study 15479705 — intervention group
Group type: EXPERIMENTAL
Intervention: PACE intervention
Number of subjects: 29
Study 12296775 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultra Sonex Ultima (electric toothbrush)
Number of subjects: 64
Study 12296775 — intervention group
Group type: COMPARATOR
Intervention: Conventional manual toothbrush
Number of subjects: 64
Study 10063307 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alpha-2b (IFN alpha-2b) with prednisolone withdrawal
Number of subjects: 32
Study 10063307 — intervention group
Group type: COMPARATOR
Intervention: Conventional hepatotonics
Number of subjects: 32
Study 8803516 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 mg imidapril
Number of subjects: 24
Study 8803516 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg imidapril
Number of subjects: 24
Study 1611460 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary calcium supplementation (1.25 g day‐1)
Number of subjects: 14
Study 1611460 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 6322734 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefoperazone sodium
Number of subjects: 80
Study 6322734 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotaxime sodium
Number of subjects: 80
Study 6322734 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 31371195 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided lumbar plexus and sciatic nerve blocks with ropivacaine (1.5 mg kg‐1)
Number of subjects: 20
Study 31371195 — intervention group
Group type: COMPARATOR
Intervention: Sham blocks with saline
Number of subjects: 20
Study 30305186 — intervention group
Group type: EXPERIMENTAL
Intervention: Partograph utilization
Number of subjects: 198
Study 30305186 — intervention group
Group type: EXPERIMENTAL
Intervention: Diploma holders
Number of subjects: 198
Study 30305186 — intervention group
Group type: EXPERIMENTAL
Intervention: Basic emergency obstetrics and newborn care training
Number of subjects: 198
Study 30305186 — intervention group
Group type: EXPERIMENTAL
Intervention: Age between 20 and 29 years
Number of subjects: 198
Study 30305186 — intervention group
Group type: EXPERIMENTAL
Intervention: Male health care providers
Number of subjects: 198
Study 27765750 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose ebselen (150 mg po twice daily)
Number of subjects: 26
Study 27765750 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 26
Study 24607602 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiotherapist-led cycle ergometer exercise (30 min, moderate intensity) plus one equivalent unsupervised exercise session, 8-week duration.
Number of subjects: 59
Study 24607602 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group).
Number of subjects: 59
Study 22889179 — intervention group
Group type: EXPERIMENTAL
Intervention: Desensitizing dentifrice
Number of subjects: 10
Study 22889179 — intervention group
Group type: EXPERIMENTAL
Intervention: Desensitizing dentifrice + CO2 laser
Number of subjects: 10
Study 22889179 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride anticavity dentifrice
Number of subjects: 10
Study 22889179 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride anticavity dentifrice + CO2 laser
Number of subjects: 10
Study 19902197 — intervention group
Group type: EXPERIMENTAL
Intervention: Racecadotril 100 mg every 8 h
Number of subjects: 0
Study 19902197 — intervention group
Group type: COMPARATOR
Intervention: Loperamide 2.0 mg followed by one tablet after each unformed stool, up to four tablets in any 24-h period
Number of subjects: 0
Study 19902197 — intervention group
Group type: EXPERIMENTAL
Intervention: Racecadotril
Number of subjects: 0
Study 19902197 — intervention group
Group type: COMPARATOR
Intervention: Loperamide
Number of subjects: 0
Study 17923225 — intervention group
Group type: EXPERIMENTAL
Intervention: Self‐etching primer (Clearfil SE Bond, CSE) with no conditioning
Number of subjects: 35
Study 17923225 — intervention group
Group type: EXPERIMENTAL
Intervention: Self‐etching primer (CSE) with 30-40% phosphoric acid (PA) preconditioning after bleaching
Number of subjects: 35
Study 17923225 — intervention group
Group type: EXPERIMENTAL
Intervention: Self‐etching primer (CSE) with 15% EDTA preconditioning after TM application
Number of subjects: 35
Study 17923225 — intervention group
Group type: EXPERIMENTAL
Intervention: Self‐etching primer (CSE) with 20% polyacrylic acid conditioner (Cavity conditioner, CC) preconditioning after TM application
Number of subjects: 35
Study 17923225 — intervention group
Group type: COMPARATOR
Intervention: Total‐etch adhesive (Single Bond, SB)
Number of subjects: 35
Study 17923225 — intervention group
Group type: EXPERIMENTAL
Intervention: Self‐etching primer (CSE) without preconditioning after TM application
Number of subjects: 35
Study 17923225 — intervention group
Group type: EXPERIMENTAL
Intervention: Self‐etching primer (CSE) after bleaching with and without TM application
Number of subjects: 35
Study 16198201 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate-release morphine
Number of subjects: 14
Study 11834103 — intervention group
Group type: EXPERIMENTAL
Intervention: DAER training (3 sets of 10 repetitions with a concentric load of 75% 1RM and an eccentric load of approximately 120% 1RM)
Number of subjects: 18
Study 11834103 — intervention group
Group type: COMPARATOR
Intervention: DCER training (4 sets of 10 repetitions with a load of 75% concentric 1RM)
Number of subjects: 18
Study 9620116 — intervention group
Group type: EXPERIMENTAL
Intervention: PHT sodium solution 435 mg intravenously
Number of subjects: 10
Study 9620116 — intervention group
Group type: COMPARATOR
Intervention: PHT acid suspension 400 mg
Number of subjects: 10
Study 9620116 — intervention group
Group type: EXPERIMENTAL
Intervention: PHT sodium solution 435 mg
Number of subjects: 10
Study 7613158 — intervention group
Group type: EXPERIMENTAL
Intervention: Zileuton (5-lipoxygenase inhibitor)
Number of subjects: 0
Study 2191992 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of methylprednisolone (40 mg bolus)
Number of subjects: 6
Study 2191992 — intervention group
Group type: EXPERIMENTAL
Intervention: Divided regimen of methylprednisolone (20 mg bolus and 5 mg bolus 8 hours later)
Number of subjects: 6
Study 2191992 — intervention group
Group type: COMPARATOR
Intervention: Both regimens of methylprednisolone
Number of subjects: 6
Study 475363 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminoglycoside treatment (gentamicin, tobramycin, or amikacin)
Number of subjects: 391
Study 31679069 — intervention group
Group type: EXPERIMENTAL
Intervention: Early functional mobilization (encouraging full weightbearing and ankle motion in orthosis)
Number of subjects: 150
Study 31679069 — intervention group
Group type: COMPARATOR
Intervention: Treatment-as-usual (2 weeks of unloading in plaster cast followed by 4 weeks weightbearing in orthosis)
Number of subjects: 150
Study 31679069 — intervention group
Group type: EXPERIMENTAL
Intervention: Early functional mobilization
Number of subjects: 150
Study 31097854 — intervention group
Group type: EXPERIMENTAL
Intervention: BB + Amiodarone
Number of subjects: 240
Study 31097854 — intervention group
Group type: COMPARATOR
Intervention: BB (comparator)
Number of subjects: 240
Study 31097854 — intervention group
Group type: EXPERIMENTAL
Intervention: BB + Rosuvastatin
Number of subjects: 240
Study 28072888 — intervention group
Group type: EXPERIMENTAL
Intervention: Simeprevir plus peg‐interferon/ribavirin (PR) for 12 weeks followed by 12 or 36 weeks of PR
Number of subjects: 1160
Study 28072888 — intervention group
Group type: EXPERIMENTAL
Intervention: Early on-treatment response at Week 4
Number of subjects: 1160
Study 25726515 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute kidney injury alert (text-based alert sent to the covering provider and unit pharmacist)
Number of subjects: 2393
Study 25726515 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 2393
Study 25726515 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute kidney injury alert
Number of subjects: 2393
Study 23771840 — intervention group
Group type: EXPERIMENTAL
Intervention: DSME/T plus MARI CD
Number of subjects: 199
Study 23771840 — intervention group
Group type: EXPERIMENTAL
Intervention: DSME/T plus MT
Number of subjects: 199
Study 23771840 — intervention group
Group type: COMPARATOR
Intervention: DSME/T alone
Number of subjects: 199
Study 21561391 — intervention group
Group type: COMPARATOR
Intervention: Chapattis containing 0% β-glucan
Number of subjects: 10
Study 21561391 — intervention group
Group type: EXPERIMENTAL
Intervention: Chapattis containing 4% β-glucan
Number of subjects: 10
Study 21561391 — intervention group
Group type: EXPERIMENTAL
Intervention: Chapattis containing 8% β-glucan
Number of subjects: 10
Study 19425198 — intervention group
Group type: EXPERIMENTAL
Intervention: Hexadecyloxypropyl‐cidofovir (CMX001)
Number of subjects: 0
Study 19425198 — intervention group
Group type: EXPERIMENTAL
Intervention: Hexadecyloxypropyl‐tenofovir (CMX157)
Number of subjects: 0
Study 19425198 — intervention group
Group type: EXPERIMENTAL
Intervention: Alkoxyalkyl esters of cidofovir and (S)‐HPMPA
Number of subjects: 0
Study 17623958 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous PCA tramadol (loading dose of 2.5 mg/kg followed by PCA infusion of 10 mg)
Number of subjects: 160
Study 17623958 — intervention group
Group type: COMPARATOR
Intervention: Intravenous PCA morphine (loading dose of 0.1 mg/kg followed by PCA morphine bolus of 1 mg)
Number of subjects: 160
Study 17623958 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous PCA tramadol
Number of subjects: 160
Study 17623958 — intervention group
Group type: COMPARATOR
Intervention: Intravenous PCA morphine
Number of subjects: 160
Study 17623958 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 160
Study 14586478 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive care strategies
Number of subjects: 304
Study 14586478 — intervention group
Group type: EXPERIMENTAL
Intervention: Infection-associated complications
Number of subjects: 304
Study 14586478 — intervention group
Group type: EXPERIMENTAL
Intervention: Infectious complications
Number of subjects: 304
Study 14586478 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood stream infections
Number of subjects: 304
Study 14586478 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumonia
Number of subjects: 304
Study 14586478 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutropenia
Number of subjects: 304
Study 14586478 — intervention group
Group type: EXPERIMENTAL
Intervention: Invasive fungal infection
Number of subjects: 304
Study 11157376 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg of warfarin daily for 12 months
Number of subjects: 76
Study 11157376 — intervention group
Group type: COMPARATOR
Intervention: Disease control group (30 healthy volunteers)
Number of subjects: 76
Study 11157376 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment group (n = 29)
Number of subjects: 76
Study 11157376 — intervention group
Group type: COMPARATOR
Intervention: Disease control group (n = 31)
Number of subjects: 76
Study 11157376 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment group
Number of subjects: 76
Study 9395349 — intervention group
Group type: EXPERIMENTAL
Intervention: Zanamivir (GG167) intranasally as prophylaxis
Number of subjects: 185
Study 9395349 — intervention group
Group type: EXPERIMENTAL
Intervention: Zanamivir (GG167) intranasally as early treatment
Number of subjects: 185
Study 9395349 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 185
Study 8203783 — intervention group
Group type: EXPERIMENTAL
Intervention: Daflon 500 mg (micronized flavonoidic fraction)
Number of subjects: 90
Study 8203783 — intervention group
Group type: COMPARATOR
Intervention: Nonmicronized diosmin
Number of subjects: 90
Study 8203783 — intervention group
Group type: EXPERIMENTAL
Intervention: Daflon 500 mg
Number of subjects: 90
Study 3302568 — intervention group
Group type: EXPERIMENTAL
Intervention: Naftidrofuryl (Dusodril) in combination with cortison and dextran
Number of subjects: 151
Study 3302568 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifyllin (Trental) in combination with cortison and dextran
Number of subjects: 151
Study 3302568 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term treatment with either naftidrofuryl or pentoxifyllin
Number of subjects: 151
Study 29495483 — intervention group
Group type: EXPERIMENTAL
Intervention: Household water treatment systems (biosand zeolite-silver impregnated granular clay filters and silver-impregnated porous pot filters) installed in 372 participants from 70 households.
Number of subjects: 480
Study 29495483 — intervention group
Group type: COMPARATOR
Intervention: Control group (108 participants from 18 households who did not accept the installation of the systems).
Number of subjects: 480
Study 24622667 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepwise addition of bolus insulin (one bolus dose with the largest meal, additional doses at 11 and 22 weeks if HbA1c remained at 7% or higher)
Number of subjects: 401
Study 24622667 — intervention group
Group type: COMPARATOR
Intervention: Full basal-bolus therapy (insulin aspart before every meal)
Number of subjects: 401
Study 22537390 — intervention group
Group type: EXPERIMENTAL
Intervention: Mother/infant skin-to-skin contact (SSC)
Number of subjects: 90
Study 22537390 — intervention group
Group type: COMPARATOR
Intervention: Control group (little or no SSC)
Number of subjects: 90
Study 19437243 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided active play/physical activity, 60 minutes, twice a week for 5 months
Number of subjects: 60
Study 19437243 — intervention group
Group type: COMPARATOR
Intervention: Control group (dietary advice and encouragement to increase physical activity only)
Number of subjects: 60
Study 18325693 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol dose of 0.65 g/kg
Number of subjects: 14
Study 18325693 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 15769980 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg dexamethasone twice daily for 5 days
Number of subjects: 25
Study 15769980 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 12479641 — intervention group
Group type: EXPERIMENTAL
Intervention: DFDBA/MGCSH
Number of subjects: 13
Study 12479641 — intervention group
Group type: COMPARATOR
Intervention: DFDBA/ePTFE
Number of subjects: 13
Study 10401515 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone (0, 0.8, 1.6, or 3.2 mg/70 kg)
Number of subjects: 20
Study 10401515 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone (lower doses)
Number of subjects: 20
Study 10401515 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone challenge
Number of subjects: 20
Study 7745488 — intervention group
Group type: EXPERIMENTAL
Intervention: Facilitated tucking
Number of subjects: 30
Study 7745488 — intervention group
Group type: COMPARATOR
Intervention: No facilitated tucking
Number of subjects: 30
Study 1693037 — intervention group
Group type: EXPERIMENTAL
Intervention: Allylestrenol (ALE) 50 mg/day for 12 weeks
Number of subjects: 58